Rubicon Research sets Aug 26 for 27th AGM; Aug 7 as Record Date for ₹1.50 dividend
Rubicon Research will hold its 27th AGM on August 26, 2026. The record date for a final dividend of ₹1.50 per share for FY26 is August 7, 2026. The company also approved the merger of its wholly-owned subsidiary, Kia Health Tech Private Limited, with Rubicon Research Limited, effective April 1, 2026.
The announcement details the final dividend payment and the approval of a subsidiary merger. The dividend has a direct financial impact on shareholders, and the merger, while internal, is a significant corporate restructuring event.
The announcement primarily concerns procedural corporate actions like setting AGM dates, record dates for dividends, and approving a subsidiary merger. While the dividend is positive, the merger is a restructuring within the group with no immediate financial impact, hence the neutral sentiment.
Rubicon Research Limited announced that its 27th Annual General Meeting (AGM) will be held on Wednesday, August 26, 2026, through Video Conferencing / Other Audio Visual Means.
The company has fixed Friday, August 7, 2026, as the 'Record Date' for determining eligible members for the payment of a final dividend of ₹1.50 per equity share (face value ₹1/- each) for the financial year 2025-26. This dividend was recommended by the Board of Directors on May 29, 2026, and is subject to member approval and tax deductions. The payment will be made within 30 days of approval to members and beneficial owners recorded as of the close of business hours on the record date.
Furthermore, the Board approved the Scheme of Merger for Kia Health Tech Private Limited, a wholly-owned subsidiary, with Rubicon Research Limited, under Section 233 of the Companies Act, 2013. The Appointed Date for this merger is April 1, 2026. As Kia Health Tech is a wholly-owned subsidiary, no new shares will be issued, and no consideration will be payable, resulting in no change to the company's shareholding pattern or voting rights. The scheme is still subject to necessary statutory, regulatory, shareholder, and creditor approvals.
The Board meeting commenced at 4:30 PM IST and concluded at 5:00 PM IST on July 20, 2026.
What to do with a filing like this
Rubicon Research Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rubicon Research Limited. Read the original for the full detail.